Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Recent Survey Suggests Complications With Permanent Fillers - 1 In 4 UK Surgeons Have Seen Patients With Complications
A new survey completed by the British Association of Aesthetic Plastic Surgery (BAAPS) suggests that patients may experience higher complication rates with permanent cosmetic fillers than with other types of cosmetic injections. The survey reveals 38.5% of surgeons saw 1-3 patients over the past year experiencing complications with permanent facial fillers, and 23% of surgeons saw 1-3 patients in the past year with complications so severe surgery was needed to treat those complications. "Permanent fillers present challenges, particularly for inexperienced injectors," says Coalition leader Julius Few, MD, a plastic surgeon practicing in Chicago, IL. "In addition to potential complications that may develop years after injection, the challenge of a permanent, synthetic filler is the anticipation of aging changes and the need for outcomes that will not look unnatural over time. To date, fat continues to be the option closest to a permanent filler with a proven safety record."
generic viagra online
FDA Approves NovoLog(R) Labeling Update - Increasing The Time Patients Can Use And Store NovoLog(R) In Their Pumps From Two Days To Six Days
Diabetes patients taking NovoLog® (insulin aspart [rDNA origin] injection) can now use the insulin in their pump for up to six days following the U.S. Food and Drug Administration (FDA) approval of a labeling change, diabetes care company Novo Nordisk announced today.[i] The previous label allowed for NovoLog® to be stored in the pump reservoir for two days. This makes NovoLog® the first and only rapid-acting insulin with this extended in-use time.
News of the day
NeurogesX Announces New PDUFA Date For Qutenza(TM) New Drug Application
NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date from August 16, 2009 to November 16, 2009 to review the new drug application (NDA) for Qutenza(TM) to manage pain associated with postherpetic neuralgia (PHN).
Cardiovascular

Dr. David B. Samadi Introduces New Prostate Cancer Care Center For Robotic Surgery Patients At Mount Sinai Medical Center

The Mount Sinai Medical Center has a new re center for prostate cancer treatment. Led by David B. Samadi, M.D., Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology, the new state-of-the-art facility at 625 Madison Avenue in New York City specializes in pre- and post-surgery care for patients who undergo a robotic prostatectomy at Mount Sinai"s main campus. It also provides expertise in the treatment of other urologic cancers, including bladder and kidney. A multilingual staff offers assistance with patient travel arrangements, accommodations, and translation services when required. "The care that patients receive before and after undergoing robotic surgery is as crucial to their recovery as the procedure itself," said Dr. Samadi. "At our new facility, patients are welcomed by a caring and compassionate staff that is ready to answer their questions on a variety of issues, including concerns about their continence, kegel exercises and sexual health. There"s an ample array of learning materials and brochures, and high-definition TV screens play educational tapes, presentations and DVDs. By the time I see my patients, they are at ease, well-informed and ready to take the next steps in their prostate care. Once they undergo robotic surgery at Mount Sinai"s main campus, our new facility offers them the additional care that they need on their road to recovery." Also known as Robotic Assisted Laparoscopic Prostatectomy, robotic prostatectomy is a minimally invasive type of prostate cancer surgery that utilizes a robotic surgical unit called the da Vinci system, manufactured by Intuitive Surgical. This prostate surgery is a revolutionary and advanced procedure that profoundly reduces blood loss, pain, recovery time, hospital stays, trauma to surrounding tissue and the drastically reduced side effects of other treatments such as incontinence and sexual dysfunction. "Our goal," Dr. Samadi says, "is not just survival, but to improve the patients" quality of life." One of the nation"s leading urologic oncologists, specializing in robotics and minimally invasive surgery for prostate cancer, Dr. Samadi has achieved great success treating more than 1,800 prostate cancer patients from around the world. He is one of very few urologic oncologic surgeons in the United States trained in all three primary areas of surgery -- open, laparoscopic, and robotic. Patients interested in obtaining more information about Mount Sinai"s new prostate cancer care facility and Robotic Assisted Laparoscopic Prostatectomy may call 212-241-8779 or visit, http://www.roboticoncology.com. The Mount Sinai Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009